Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Siplizumab - ITBMed Biopharmaceuticals

Drug Profile

Siplizumab - ITBMed Biopharmaceuticals

Alternative Names: MEDI-507

Latest Information Update: 31 Jul 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Catholic University of Louvain
  • Developer BioTransplant (CEASED); MedImmune
  • Class Antipsoriatics; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; CD2 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Transplant rejection
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Graft-versus-host disease; Psoriasis; Psoriatic arthritis; Renal transplant rejection; Rheumatoid arthritis; T-cell lymphoma

Most Recent Events

  • 23 Jul 2018 ITBMed Biopharmaceuticals plans phase III development of siplizumab
  • 24 Jun 2018 Biomarkers information updated
  • 15 Feb 2018 Siplizumab - ITBMed Biopharmaceuticals receives Orphan Drug status for Transplant rejection (Prevention) in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top